Eyenovia Stock Discussion

$Eyenovia (EYEN.US)$
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
Eyenovia, Inc. (NASDAQ: EYEN) announced a presentation at the American Academy of Ophthalmology (AAO) 2024 Expo, showcasing results from their successful Phase 3 study (CPN-302) of clobetasol propionate suspension 0.05%. This study led to FDA approval for treating inflammation and pain after ocular surgery. The presentation will highlight the drug's...

$Eyenovia (EYEN.US)$
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet DeviceEyenovia, Inc. (NASDAQ: EYEN) has begun manufacturing registration batches of its FDA-approved mydriasis product, Mydcombi, using the advanced Gen-2 Optejet dispensing platform. This marks a important step in the approval process for the new device, which is designed for an optimized user experience and extended patent protection through 2041.
The Gen-2 Optejet features impr...

$Eyenovia (EYEN.US)$ Reuters· just
Eyenovia : Commenced Manufacturing of Registration Batches of Its FDA-Approved Mydriasis Product, Mydcombi

$Eyenovia (EYEN.US)$
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN) ("Eyenovia" or the "Company"), an ophthalmic technology company with two FDA-approved products and a late-stage asset in development for the treatment of pediatric progressive myopia, today announced it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale o...

$Eyenovia (EYEN.US)$ Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery

$Eyenovia (EYEN.US)$ The way you took off in PM. Thought you was gonna close the gap to .6802? Grrrr. Well you still look decent. So lets get to it and close away! Hehehe

$Eyenovia (EYEN.US)$ Formosa Pharma and Eyenovia Set to Launch New FDA-Approved Ophthalmic Drug in US
Benzinga· 03:02

$Eyenovia (EYEN.US)$
Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization
Formosa Pharmaceuticals (6838.TW) has made its first shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for commercialization. The drug, developed using Formosa's APNT® nanotechnology platform, is the first FDA-approved ophthalmic use of the super-potent corticosteroid, clobetas...

$Eyenovia (EYEN.US)$
Formosa Pharma and Eyenovia Set to Launch New FDA-Approved Ophthalmic Drug in US